Welcome to our dedicated page for UroGen Pharma Ltd. Ordinary Shares news (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on UroGen Pharma Ltd. Ordinary Shares stock.
UroGen Pharma Ltd. (Nasdaq: URGN) is a clinical-stage biopharmaceutical company dedicated to developing innovative non-surgical treatments for urological conditions, particularly uro-oncology. The company is headquartered in Ra’anana, Israel, with its U.S. headquarters in New York.
UroGen’s core technology, RTGel™, is a proprietary sustained-release, hydrogel-based platform designed to improve drug delivery and efficacy. By prolonging the exposure of the urinary tract tissue to medications, RTGel™ aims to make local therapies more effective. This innovative approach addresses significant unmet needs in the field of urology.
The company’s lead product candidates include Mitogel™ (mitomycin urothelial gel) and Vesigel™ (mitomycin intravesical gel). Both products target non-surgical tumor ablation in non-muscle invasive urothelial cancers. Mitogel™ is specifically designed to treat low-grade upper tract urothelial carcinoma, while Vesigel™ aims to treat bladder cancer.
Additionally, UroGen's commercial product, Jelmyto (mitomycin) for pyelocalyceal solution, has shown promise in treating patients. Their investigational candidate, UGN-102 (mitomycin) for intravesical solution, is in development for bladder cancer treatment.
UroGen is also advancing its immuno-uro-oncology pipeline with UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, which is being explored for both monotherapy and combination therapy.
Through strategic partnerships, cutting-edge research, and a commitment to addressing complex medical challenges, UroGen Pharma continues to push the boundaries in the treatment of urothelial diseases.
UroGen Pharma announced promising results from the Phase 2b OPTIMA II trial for UGN-102, a non-surgical treatment for low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). The trial showed a 65% complete response rate at three months, with 61% of patients maintaining complete response at 12 months. The data supports ongoing Phase 3 development, indicating UGN-102's potential as a primary therapy for this patient demographic, which currently relies heavily on surgical interventions.
UroGen Pharma Ltd. (URGN), a biopharmaceutical company focused on specialty cancers and urologic diseases, will present at the Cantor Fitzgerald 2021 Virtual Global Healthcare Conference on September 30, 2021, at 3:20 p.m. ET. A live webcast will be accessible on UroGen’s website, with a replay available for 30 days. UroGen is known for its proprietary RTGel™ technology, aimed at enhancing drug delivery in urology. The company’s initial product, UGN-102, targets low-grade non-muscle invasive bladder cancer through non-surgical means.
UroGen Pharma Ltd. (NASDAQ: URGN) announced key results from the Phase 2b OPTIMA II trial of UGN-102, where 65% of patients with low-grade intermediate risk NMIBC achieved complete response at three months. Additionally, the Phase 3 OLYMPUS trial of Jelmyto revealed a 58% complete response rate in low-grade upper tract urothelial cancer patients, with an 81.8% durability rate at 12 months. Both trials were presented at the AUA Annual Meeting and highlight UroGen's focus on non-surgical treatments for urinary cancers.
UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13, 2021, through the conference portal and UroGen's website. UroGen focuses on developing innovative treatments for specialty cancers and urologic diseases, with its proprietary RTGel™ technology enhancing drug delivery to the urinary tract. Its investigational product, UGN-102, targets low-grade non-muscle invasive bladder cancer.
UroGen Pharma Ltd. (Nasdaq: URGN) announced the grant of inducement restricted stock units (RSUs) to 19 new employees. This initiative supports the ongoing launch of Jelmyto® for pyelocalyceal solution, UroGen's first approved product, and the development of its pipeline. A total of 94,800 shares of common stock are issuable upon the vesting of these RSUs, which will vest equally over three years. The RSUs comply with Nasdaq Rule 5635(c)(4) and are part of the company's 2019 Inducement Plan.
UroGen Pharma Ltd. (Nasdaq: URGN) reported financial results for Q2 2021, highlighting strong revenue growth from its product Jelmyto, which generated $13.0 million, a 70% increase from Q1 2021. The company has activated 407 treatment sites, a 29% rise since May. UGN-102's pivotal Phase 3 ATLAS trial continues with nearly 100 sites enrolled. UroGen's net loss was $26.2 million with a cash position of $129.3 million as of June 30, 2021. The company anticipates operating expenses between $155 to $165 million for the year.
UroGen Pharma Ltd. (Nasdaq: URGN) has entered into an exclusive licensing agreement with Neopharm to market Jelmyto (mitomycin) in Israel, pending regulatory approval. Jelmyto is the first FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC). Neopharm will handle the regulatory processes, supported by successful Phase 3 OLYMPUS trial results. UroGen aims to expand Jelmyto's availability beyond the U.S., emphasizing Israel's significance due to its foundational ties and local clinical trial contributions.
UroGen Pharma Ltd. (Nasdaq: URGN) will report its second quarter 2021 financial results on August 4, 2021, before market opening. The company will hold a live audio webcast and conference call at 8:30 AM Eastern Time to discuss these results. UroGen specializes in biopharmaceutical solutions for specialty cancers and urologic diseases, with its first commercial product being UGN-102, an investigational treatment for low-grade non-muscle invasive bladder cancer. More information can be accessed through UroGen's investor relations webpage.
UroGen Pharma Ltd. (Nasdaq: URGN) announced expected net product revenue from Jelmyto sales of approximately $13 million for Q2 2021, marking a 70% increase from Q1 2021 and the highest since its launch in June 2020. Operating expenses are anticipated to be between $33 to $38 million. As of June 30, 2021, cash and equivalents are projected at $129 million. The company reaffirms its full-year operating expense guidance of $155 to $165 million. UroGen plans to report complete Q2 results on August 4, 2021.
UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company specializing in treatments for urologic diseases and specialty cancers, will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 12:00 PM ET. A live webcast of the event will be accessible on the Investors section of UroGen's website. The company is known for its innovative RTGel™ technology, enhancing drug delivery for bladder cancer treatments, including its investigational product UGN-102. The webcast replay will be available for 30 days.
FAQ
What is the current stock price of UroGen Pharma Ltd. Ordinary Shares (URGN)?
What is the market cap of UroGen Pharma Ltd. Ordinary Shares (URGN)?
What is UroGen Pharma Ltd. (URGN)?
What is RTGel™?
What are UroGen’s lead product candidates?
Where is UroGen Pharma headquartered?
What is Jelmyto?
What is UGN-102?
What is UroGen’s UGN-301?
What types of cancer is UroGen Pharma focusing on?
How does UroGen Pharma generate revenue?
What is the mission of UroGen Pharma?
